A dose-response study of the bronchodilator action of azelastine in asthma.
Azelastine is an orally effective inhibitor of mediator activity in allergic reactions and has also been demonstrated to have bronchodilator activity. In this randomized, double-blind, placebo-controlled, multicenter study, 150 patients, aged 12 to 60 years, with moderate to severe asthma, received a single oral dose of 2, 4, 8, 12, or 16 mg of azelastine or placebo. Theophylline was stopped 24 hours and other bronchodilators at least 8 hours before the study day. Patients were evaluated for 8 hours after dose by spirometry and were monitored for adverse effects. All doses of azelastine produced bronchodilation with 4 mg greater than 2 mg greater than placebo; higher doses did not increase magnitude or duration of effect. We conclude that azelastine produces significant bronchodilation of long duration. The optimal dose appears to be 4 mg for adolescent and adult patients with asthma.
Kemp
J P
JP
Meltzer
E O
EO
Orgel
H A
HA
Welch
M J
MJ
Bucholtz
G A
GA
Middleton
E
E
Spector
S L
SL
Newton
J J
JJ
Perhach
J L
JL
D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D007700:Kinetics; D008176:Lung Volume Measurements; D008875:Middle Aged; D010793:Phthalazines / Q000627:therapeutic use*; D011724:Pyridazines / Q000627:therapeutic use*; D011897:Random Allocation; D013806:Theophylline / Q000097:blood
D001993:Bronchodilator Agents; D010793:Phthalazines; D011724:Pyridazines; D013806:Theophylline; C020976:azelastine